- Senior management team possessing over 130 years of cumulative expertise
PRINCETON, N.J. and SAN DIEGO, June 30 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical stage biotechnology company committed to the research and product discovery against life-threatening and life-altering infectious diseases, today announced the organization of the company's senior management team. Tobira Therapeutics has been led since its inception in 2006 by James Sapirstein, RPh, MBA as Chief Executive Officer and President. Joining James is Sandra Palleja, MD, Executive Vice-President and Chief Medical Officer, Angeline Shashlo, RPh, Senior Vice-President Regulatory Affairs and Quality Assurance, and Jay Rheingold, PhD, Vice-President Chemistry Manufacturing and Controls. These additions continue to build the management team with world-class pharmaceutical development experts. "With this senior management team Tobira Therapeutics has more than 130 years of combined pharmaceutical experience, with the majority focused in biotech companies or HIV compounds. We are perfectly positioned to bring novel molecules to market that will play an important role in the treatment of HIV infection".
Dr. Palleja is the Chief Medical Officer, responsible for the overall
clinical development of the Tobira Therapeutics portfolio. Sandra joined
Tobira from Shionogi USA, where she lead numerous clinical programs as Vice
President of Clinical Development in several therapeutic categories
including an HIV joint venture with GSK. Prior to her years at Shionogi,
Sandra gained additional experience from both Triangle Pharmaceutics and
Hoffman-LaRoche, where she helped develop a variety of antivirals for HIV
and hepatitis including FTC, DAPD, ganciclovir, and saquinavir. Prior to
her career in industry, she was the Director of the Infectious Diseases
Clinic at St. Vincent's Hospital and Medical Center of New York City during
the mid to late 90's. Pri
|SOURCE Tobira Therapeutics Inc.|
Copyright©2008 PR Newswire.
All rights reserved